Summary
102.08 -3.26(-3.09%)09/06/2024
Lantheus Holdings Inc (LNTH)
Lantheus Holdings Inc (LNTH)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -3.06 | -4.12 | 3.86 | 25.00 | 64.99 | 52.97 | 353.49 | 1,407.83 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 102.08 | |
| Open | 105.71 | |
| High | 108.18 | |
| Low | 101.92 | |
| Volume | 407,288 | |
| Change | -3.22 | |
| Change % | -3.06 | |
| Avg Volume (20 Days) | 554,753 | |
| Volume/Avg Volume (20 Days) Ratio | 0.73 | |
| 52 Week Range | 50.20 - 126.89 | |
| Price vs 52 Week High | -19.55% | |
| Price vs 52 Week Low | 103.35% | |
| Range | -3.43 | |
| Gap Up/Down | -1.73 | |
Fundamentals | ||
| Market Capitalization (Mln) | 7,081 | |
| EBIDTA | 544,540,032 | |
| PE Ratio | 11.5884 | |
| PEG Ratio | 0.6100 | |
| WallStreet Target Price | 104.40 | |
| Book Value | 13.6450 | |
| Earnings Per Share | 6.5600 | |
| EPS Estimate Current Quarter | 1.5400 | |
| EPS Estimate Next Quarter | 1.7200 | |
| EPS Estimate Current Year | 7.1100 | |
| EPS Estimate Next Year | 6.6600 | |
| Diluted EPS (TTM) | 6.5600 | |
| Revenues | ||
| Profit Marging | 0.3372 | |
| Operating Marging (TTM) | 0.2713 | |
| Return on asset (TTM) | 0.1901 | |
| Return on equity (TTM) | 0.6621 | |
| Revenue TTM | 1,365,619,968 | |
| Revenue per share TTM | 19.9310 | |
| Quarterly Revenue Growth (YOY) | 0.2300 | |
| Quarterly Earnings Growth (YOY) | 1.1860 | |
| Gross Profit (TTM) | 581,703,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 11.5884 | |
| Forward PE | 9.2507 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 5.1084 | |
| Revenue Enterprise Value | 3.1403 | |
| EBITDA Enterprise Value | 8.2916 | |
| Shares | ||
| Shares Outstanding | 69,312,600 | |
| Shares Float | 67,889,601 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.09 | |
| Insider (%) | 2.54 | |
| Institutions (%) | 103.66 | |
09/05 08:30 EST - globenewswire.com
Lantheus Appoints Julie Eastland as New Board Member
BEDFORD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Julie Eastland, an experienced biotechnology and financial executive, to Lantheus' Board of Directors (“Board”), effective as of September 3, 2024. As an independent director, Ms. Eastland will serve as a member of the Board's Audit Committee. Following the appointment of Ms. Eastland, the Board will be comprised of ten directors, eight of whom are independent.
Lantheus Appoints Julie Eastland as New Board Member
BEDFORD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Julie Eastland, an experienced biotechnology and financial executive, to Lantheus' Board of Directors (“Board”), effective as of September 3, 2024. As an independent director, Ms. Eastland will serve as a member of the Board's Audit Committee. Following the appointment of Ms. Eastland, the Board will be comprised of ten directors, eight of whom are independent.
08/28 08:30 EST - globenewswire.com
Lantheus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
BEDFORD, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Brian Markison, Chief Executive Officer, will present at the Morgan Stanley 22nd Annual Global Healthcare Conference at 7:45 a.m. ET on Wednesday, September 4.
Lantheus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
BEDFORD, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Brian Markison, Chief Executive Officer, will present at the Morgan Stanley 22nd Annual Global Healthcare Conference at 7:45 a.m. ET on Wednesday, September 4.
08/12 15:32 EST - seekingalpha.com
Lantheus: A Radiopharmaceutical Powerhouse In The Making (Q2 2024 Update)
PYLARIFY is the leading PSMA PET imaging agent, on track to surpass $1 billion in sales by 2024, driving significant revenue growth for Lantheus Holdings, Inc. Lantheus is heavily investing in its oncology and Alzheimer's diagnostics pipeline, positioning itself for substantial long-term growth despite short-term profit impacts. With robust free cash flow, a solid balance sheet, and potential for significant EPS growth, Lantheus Holdings is undervalued and could reach $250 per share by 2028.
Lantheus: A Radiopharmaceutical Powerhouse In The Making (Q2 2024 Update)
PYLARIFY is the leading PSMA PET imaging agent, on track to surpass $1 billion in sales by 2024, driving significant revenue growth for Lantheus Holdings, Inc. Lantheus is heavily investing in its oncology and Alzheimer's diagnostics pipeline, positioning itself for substantial long-term growth despite short-term profit impacts. With robust free cash flow, a solid balance sheet, and potential for significant EPS growth, Lantheus Holdings is undervalued and could reach $250 per share by 2028.
08/12 07:15 EST - marketwatch.com
13 stocks to consider if you're able to brave recession fears
Now that stock investors are beginning to realize that a recession isn't on the way, the U.S. market will get back to doing what is up to before the August swoon: showing strength beyond the Magnificent Seven.
13 stocks to consider if you're able to brave recession fears
Now that stock investors are beginning to realize that a recession isn't on the way, the U.S. market will get back to doing what is up to before the August swoon: showing strength beyond the Magnificent Seven.
07/31 07:00 EST - globenewswire.com
Lantheus Reports Second Quarter 2024 Financial Results
Second Quarter 2024 Worldwide revenue of $394.1 million, an increase of 22.5% from second quarter 2023 Completed three strategic transactions to expand innovative pipeline GAAP fully diluted earnings per share of $0.88, compared to $1.33 in second quarter 2023. Adjusted fully diluted earnings per share of $1.80 compared to $1.54 in the second quarter 2023, reflective of inter-quarter investment in business development and R&D.
Lantheus Reports Second Quarter 2024 Financial Results
Second Quarter 2024 Worldwide revenue of $394.1 million, an increase of 22.5% from second quarter 2023 Completed three strategic transactions to expand innovative pipeline GAAP fully diluted earnings per share of $0.88, compared to $1.33 in second quarter 2023. Adjusted fully diluted earnings per share of $1.80 compared to $1.54 in the second quarter 2023, reflective of inter-quarter investment in business development and R&D.
07/17 08:30 EST - globenewswire.com
Lantheus to Host Second Quarter 2024 Earnings Conference Call and Webcast on July 31, 2024, at 8:00 a.m. Eastern Time
BEDFORD, Mass., July 17, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday,
Lantheus to Host Second Quarter 2024 Earnings Conference Call and Webcast on July 31, 2024, at 8:00 a.m. Eastern Time
BEDFORD, Mass., July 17, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday,
07/15 08:30 EST - globenewswire.com
Lantheus Acquires NAV-4694, a Next-Generation ß Amyloid PET Imaging Agent for Alzheimer's Disease
Acquisition Expands Pipeline and Strengthens Alzheimer's Diagnostic Capabilities Acquisition Expands Pipeline and Strengthens Alzheimer's Diagnostic Capabilities
Lantheus Acquires NAV-4694, a Next-Generation ß Amyloid PET Imaging Agent for Alzheimer's Disease
Acquisition Expands Pipeline and Strengthens Alzheimer's Diagnostic Capabilities Acquisition Expands Pipeline and Strengthens Alzheimer's Diagnostic Capabilities
07/10 12:32 EST - globenewswire.com
Lantheus Welcomes CMS' Proposed CY25 Rule for Improved Payment for Specialized Diagnostic Radiopharmaceuticals to Support Patient Access
BEDFORD, Mass., July 10, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced that it welcomes the Centers for Medicare & Medicaid Services' (CMS') Proposed Medicare Hospital Outpatient Prospective Payment System (OPPS) Rule for calendar year 2025 for improved payment for specialized diagnostic radiopharmaceuticals to support patient access for Medicare beneficiaries.
Lantheus Welcomes CMS' Proposed CY25 Rule for Improved Payment for Specialized Diagnostic Radiopharmaceuticals to Support Patient Access
BEDFORD, Mass., July 10, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced that it welcomes the Centers for Medicare & Medicaid Services' (CMS') Proposed Medicare Hospital Outpatient Prospective Payment System (OPPS) Rule for calendar year 2025 for improved payment for specialized diagnostic radiopharmaceuticals to support patient access for Medicare beneficiaries.
07/10 11:57 EST - fool.com
Why Lantheus Holdings Stock Is Skyrocketing Today
Medicare will likely soon change how it pays for diagnostic radiopharmaceuticals. Lantheus should be a big winner from this reimbursement change.
Why Lantheus Holdings Stock Is Skyrocketing Today
Medicare will likely soon change how it pays for diagnostic radiopharmaceuticals. Lantheus should be a big winner from this reimbursement change.
07/10 10:19 EST - investors.com
Lantheus Stock Gets A Radioactive Surge On Medicare Proposal
Lantheus stock rocketed to a 13-month high Wednesday after a Medicare proposal suggested hiking the reimbursement rate for some diagnostics.
Lantheus Stock Gets A Radioactive Surge On Medicare Proposal
Lantheus stock rocketed to a 13-month high Wednesday after a Medicare proposal suggested hiking the reimbursement rate for some diagnostics.
07/08 08:30 EST - globenewswire.com
Lantheus Appoints Jamie Spaeth as Chief People Officer
BEDFORD, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Jamie Spaeth to its Executive Team as Chief People Officer.
Lantheus Appoints Jamie Spaeth as Chief People Officer
BEDFORD, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Jamie Spaeth to its Executive Team as Chief People Officer.
06/27 07:05 EST - globenewswire.com
Lantheus Acquires Global Rights to Life Molecular Imaging's Novel Therapeutic and Diagnostic Pair Targeting GRPR for Prostate and Breast Cancers
Deal Further Strengthens Lantheus' Prostate Cancer Portfolio and Expands Pipeline to Include Breast Cancer Deal Further Strengthens Lantheus' Prostate Cancer Portfolio and Expands Pipeline to Include Breast Cancer
Lantheus Acquires Global Rights to Life Molecular Imaging's Novel Therapeutic and Diagnostic Pair Targeting GRPR for Prostate and Breast Cancers
Deal Further Strengthens Lantheus' Prostate Cancer Portfolio and Expands Pipeline to Include Breast Cancer Deal Further Strengthens Lantheus' Prostate Cancer Portfolio and Expands Pipeline to Include Breast Cancer
06/24 10:55 EST - zacks.com
Why Lantheus Holdings (LNTH) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Lantheus Holdings (LNTH) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
06/21 08:30 EST - zacks.com
New Strong Buy Stocks for June 21st
ASYS, LAUR, ESLT, LNTH and LMAT have been added to the Zacks Rank #1 (Strong Buy) List on June 21, 2024.
New Strong Buy Stocks for June 21st
ASYS, LAUR, ESLT, LNTH and LMAT have been added to the Zacks Rank #1 (Strong Buy) List on June 21, 2024.
06/21 06:10 EST - zacks.com
Best Value Stocks to Buy for June 21st
LAUR, ESLT and LNTH made it to the Zacks Rank #1 (Strong Buy) value stocks list on June 21, 2024.
Best Value Stocks to Buy for June 21st
LAUR, ESLT and LNTH made it to the Zacks Rank #1 (Strong Buy) value stocks list on June 21, 2024.
06/20 20:41 EST - globenewswire.com
Radiopharm Receives Strategic Investment for up to A$18 million
SYDNEY, June 20, 2024 (GLOBE NEWSWIRE) -- Radiopharm Theranostics Limited (ASX:RAD) (Radiopharm or the Company), a developer of diagnostic and therapeutic radiopharmaceutical products, has entered into strategic agreements with Lantheus Holdings, Inc. (LNTH.NASDAQ), a leading radiopharmaceutical-focused company, and its affiliates (Lantheus). Lantheus has agreed to make an initial equity investment of A$7.5 million (US$4.99 million) and will have an option to invest a further A$7.5 million (US$5 million) within 6 months on the same terms. Additionally, Radiopharm has agreed to transfer two of its early preclinical assets to Lantheus for A$3.0 million (US$2.0 million) pursuant to a separate transfer and development agreement.
Radiopharm Receives Strategic Investment for up to A$18 million
SYDNEY, June 20, 2024 (GLOBE NEWSWIRE) -- Radiopharm Theranostics Limited (ASX:RAD) (Radiopharm or the Company), a developer of diagnostic and therapeutic radiopharmaceutical products, has entered into strategic agreements with Lantheus Holdings, Inc. (LNTH.NASDAQ), a leading radiopharmaceutical-focused company, and its affiliates (Lantheus). Lantheus has agreed to make an initial equity investment of A$7.5 million (US$4.99 million) and will have an option to invest a further A$7.5 million (US$5 million) within 6 months on the same terms. Additionally, Radiopharm has agreed to transfer two of its early preclinical assets to Lantheus for A$3.0 million (US$2.0 million) pursuant to a separate transfer and development agreement.
06/19 08:30 EST - zacks.com
4 Medical Product Stocks to Buy From a Recovering Industry
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. BSX, RMD, LNTH and HAE are well-poised to gain from the favorable factors.
4 Medical Product Stocks to Buy From a Recovering Industry
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. BSX, RMD, LNTH and HAE are well-poised to gain from the favorable factors.
06/18 12:51 EST - zacks.com
Lantheus (LNTH) Gains 33.3% YTD: What's Driving the Stock?
Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.
Lantheus (LNTH) Gains 33.3% YTD: What's Driving the Stock?
Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.
06/12 17:01 EST - zacks.com
Don't Overlook These Highly Ranked Medical Stocks as Markets Rise
With earnings estimate revisions on the rise for these top medical stocks, they certainly shouldn't be overlooked given their blazing historical performances.
Don't Overlook These Highly Ranked Medical Stocks as Markets Rise
With earnings estimate revisions on the rise for these top medical stocks, they certainly shouldn't be overlooked given their blazing historical performances.
06/12 05:55 EST - zacks.com
New Strong Buy Stocks for June 12th
RDNT, ESLT, CLS, LNTH and ASBFY have been added to the Zacks Rank #1 (Strong Buy) List on June 12, 2024.
New Strong Buy Stocks for June 12th
RDNT, ESLT, CLS, LNTH and ASBFY have been added to the Zacks Rank #1 (Strong Buy) List on June 12, 2024.